Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND 76431; NSC 617807).

Trial Profile

A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND 76431; NSC 617807).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2018

At a glance

  • Drugs Lestaurtinib (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine/daunorubicin; Daunorubicin; Dexamethasone; Dexamethasone; Etoposide; Filgrastim; Filgrastim; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Pegaspargase; Prednisone; Vincristine
  • Indications Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 27 Sep 2012 New source identified and integrated (Barbara Ann Karmanos Cancer Institute).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top